A case of alemtuzumab-induced thyroid disease with a fluctuating course
Alemtuzumab (ALZ) is a humanized monoclonal antibody licensed for the treatment of relapsing–remitting multiple sclerosis (RRMS). One of its common side effects is autoimmune thyroid disease, most commonly Graves' disease (GD). Here, we present a case of a 39-year-old female that was on ALZ for...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Saudi Journal for Health Sciences |
| Subjects: | |
| Online Access: | http://www.saudijhealthsci.org/article.asp?issn=2278-0521;year=2023;volume=12;issue=2;spage=165;epage=166;aulast=Alghamdi |